The CMS has finalized the first cycle of drug price negotiations under the IRA, establishing precedent for improved ...

A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and ...

Insulin costs have declined over the past two years, and additional price cuts are expected in 2026. Medicare will lower prices for several diabetes drugs, including Januvia and Jardiance. Federal and ...

Hospitalized patients with diabetes require specialized management to reduce readmission rates and complications. Newer ...

One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.

Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, officially becoming the world’s best-selling drug. Lilly is working to shore ...